BioSkryb Genomics
BioSkryb Genomics develops patented single-cell whole genome amplification (PTA) and multiomics products — ResolveDNA, ResolveOME, BaseJumper, and ResolveSEQ kits and services — serving biopharma, academic researchers, diagnostic developers, and AI/ML companies globally.
- Company typePrivate
- Founded2018
- HeadquartersDurham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioSkryb Genomics does
BioSkryb Genomics is a US-based life sciences tools company founded in 2018 and headquartered in Durham, North Carolina, that develops and commercializes single-cell whole genome amplification and multiomics products for research, translational, and diagnostic-adjacent applications. Its core technology is Primary Template-directed Amplification (PTA), a patented isothermal whole genome amplification method using phi29 DNA polymerase with exonuclease-resistant terminators that achieves greater than 97% single-cell genome coverage and substantially higher uniformity than legacy WGA methods (DOP-PCR, MDA, MALBAC, LIANTI). The commercial portfolio includes ResolveDNA kits (single-cell DNA sequencing), ResolveOME kits (joint whole genome and full-length transcriptome from the same cell), the BaseJumper bioinformatics platform with embedded BaseJumper AI (LLM-enabled QC, variant calling, and report generation available as cloud or on-premise), ResolveSEQ application kits (MRD, ScreenHT high-throughput SNV screening, LongRead), and ResolveServices contract research services. A femtogram-scale sensitivity claim positions the technology to address 'quantity not sufficient' samples that account for up to 30% of high-volume diagnostic workflows.
The company sells primarily to biopharmaceutical companies, academic and research institutions, diagnostic developers, and AI/ML companies, with named reference customers including Beam Therapeutics, Falcon Therapeutics, Praxis Genomics, Harvard Medical School, Boston Children's Hospital, Duke University, University of Massachusetts Medical School, the Hubrecht Institute, and Oregon Health & Science University. Go-to-market is a hybrid model: direct enterprise sales in seven European countries (UK, Germany, Austria, Switzerland, Belgium, Luxembourg, Netherlands), with a global distributor network covering the rest of EMEA and Asia-Pacific including named partners in Italy, France, Iberia, Nordics, Israel, Poland, China, Japan, Korea, Australia, New Zealand, India, and Southeast Asia. Pricing is quote-based and not publicly disclosed; revenue streams comprise one-time kit and consumable sales, professional services through ResolveServices, and data monetization via AI dataset partnerships. Recent strategic activity in 2024–2025 includes partnerships with Human Cell Atlas, Tecan, Ultima Genomics, 1Cell.Ai, and Eremid Genomic Services, an exclusive methylation IP license, and multiple product launches extending into MRD and long-read applications.
BioSkryb Genomics firmographics
Firmographics- Name
- BioSkryb Genomics
- Legal name
- Bioskryb, Inc.
- Website
- https://bioskryb.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioSkryb Genomics develops patented single-cell whole genome amplification (PTA) and multiomics products — ResolveDNA, ResolveOME, BaseJumper, and ResolveSEQ kits and services — serving biopharma, academic researchers, diagnostic developers, and AI/ML companies globally.
- Ownership category
- akta.pro rank
BioSkryb Genomics industry classification
Industry- Product category
- Single-Cell Genomics Tools and Reagents
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
- akta.pro secondary industries
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
Keywords
Where BioSkryb Genomics is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioSkryb Genomics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Product Sales (Kits and Consumables): Sale of ResolveDNA and ResolveOME whole genome amplification kits, library preparation reagents, bead purification kits, and related consumables. Available in 96 and 384 reaction formats.
- Contract Services (ResolveServices): End-to-end single-cell sequencing services including cell sorting, amplification, library preparation, sequencing, and bioinformatics analysis. Managed by PhD scientists with customizable project specifications.
- AI Dataset Partnerships: Partnership with biopharma and AI/ML companies to provide high-fidelity single-cell multiomic training datasets for AI model development.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
BioSkryb Genomics product offering
Product offeringCore offering
BioSkryb Genomics develops and sells single-cell whole genome amplification kits (ResolveDNA, ResolveOME), sequencing services (ResolveSEQ MRD, ScreenHT, LongRead), and the BaseJumper bioinformatics platform, all powered by its patented Primary Template-directed Amplification (PTA) technology. The offering enables researchers to capture >97% of the genome along with full-length transcriptome and surface protein data from the same single cell in a single-day workflow.
Product overview
BioSkryb Genomics offers a platform-plus-products architecture centered on Primary Template-directed Amplification (PTA) technology. The core portfolio includes ResolveDNA for single-cell DNA sequencing, ResolveOME for single-cell multiomics (simultaneous DNA and RNA), and BaseJumper as the bioinformatics platform for QC analysis and data interpretation. The ResolveSEQ product line extends the platform with specialized applications including MRD (Minimal Residual Disease) detection, ScreenHT high-throughput screening, and LongRead sequencing. ResolveServices provides contract sequencing access to these technologies. BaseJumper is available as cloud-based (BaseJumper Cloud) or on-premise (BaseJumper Local) deployment. All products are designed to integrate with Illumina sequencing platforms.
Differentiator
Problem solved
Functional benefit
Brands
- ResolveDNA: Whole genome amplification kits for single-cell DNA sequencing
- ResolveOME
- BaseJumper
- ResolveServices
- ResolveSEQ MRD
- ResolveSEQ ScreenHT
- ResolveSEQ LongRead
Products and services
- ResolveDNA PTA-based whole genome amplification kit that reproducibly recovers greater than 95% of genomes from single cells with industry-leading uniformity and accuracy. Supports up to 384 reactions per kit and is designed for single-cell DNA sequencing researchers in academic, biopharma, and diagnostic settings.
- ResolveOME Unified single-cell whole genome and transcriptome amplification kit that provides greater than 97% genomic coverage combined with full-length mRNA transcriptome analysis from the same single cell in a single-day, automation-compatible workflow. Available in 96 and 384 reaction formats.
- BaseJumper Cloud-based and local bioinformatics platform for single-cell multiomic data analysis, quality control, variant detection, custom variant models, and AI/ML training data preparation. Includes BaseJumper AI with LLM-enabled workflows for natural language interaction with genomic data.
- ResolveSEQ MRD Single-cell DNA sequencing service and assay for minimal residual disease discovery and monitoring in hematologic malignancies, enabling more complete characterization of residual disease cells to support therapy selection.
- ResolveSEQ ScreenHT
Quantifiable outcome
- >97% genome coverage from single cells
- +2 more outcomes
Companies that use BioSkryb Genomics
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
BioSkryb Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature5 records
BioSkryb Genomics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- Eremid Genomic ServicesminorBioSkryb Certified Service Provider for ResolveSEQ LongRead Early Access Program. Eremid provides specialty high-complexity genomics contract research organization services.
- Tecan GroupcoreIntroduced high-throughput single-cell workflow combining BioSkryb's 384-well format ResolveOME kit with Tecan's automation platforms for sequencing-ready libraries in under ten hours.
- 1Cell.AicoreStrategic partnership to co-develop and commercialize next-generation single cell multi-omic solutions. Combines BioSkryb's PTA-based single-cell technology with 1Cell.Ai's single cell precision diagnostics capabilities.
- Ultima GenomicsminorJoint grant program to advance oncology research. Provides researchers with access to BioSkryb's multi-omic platforms combined with Ultima Genomics' sequencing technology.
- Human Cell AtlascorePartnership to increase global access to BioSkryb's single-cell multiomics technology. Human Cell Atlas is a global consortium creating reference maps of all human cells.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
BioSkryb Genomics competitors and assessment
Company assessmentBroad incumbents
- Illumina: Dominant sequencing platform provider whose instruments are required downstream of BioSkryb's kits. Also offers adjacent single-cell and multiomics products and partnership ecosystems that intersect with BioSkryb's value chain.
- 10x Genomics: Dominant single-cell sequencing platform (Chromium) with droplet-based partitioning for DNA and RNA. Directly competes with BioSkryb's ResolveDNA/ResolveOME in single-cell genomics, with much larger scale, broader installed base, and integrated instruments/reagents.
- Takara Bio (SMART-seq): Provides SMART-seq single-cell RNA and emerging multiomics kits; competes with ResolveDNA and ResolveOME in academic and translational research, particularly for full-length transcriptome workflows.
- BD (BD Biosciences - Rhapsody): BD's Rhapsody single-cell multiomics platform competes with BioSkryb's ResolveDNA/ResolveOME in academic and translational research markets. Backed by a large life sciences conglomerate with extensive distribution.
Emerging players
- Element Biosciences: Sequencing platform competitor to Illumina that could become an alternative downstream platform for BioSkryb's kits; represents both a potential partnership vector and a hedging opportunity against Illumina dependency.
- Parse Biosciences: Single-cell sequencing with combinatorial indexing approach (Evercode), competing in single-cell RNA and multiomics. Targets similar academic/biopharma customers as BioSkryb but with different chemistry architecture.
- Ultima Genomics: Sequencing platform that already has an active partnership with BioSkryb for oncology grant programs. A potential alternative sequencing ecosystem for ResolveSEQ and ResolveOME products.
- Singleron Biotechnologies: Single-cell multiomics platform (PythoN, GEXSCOPE) with strong APAC distribution. Competes with BioSkryb in academic/biopharma single-cell applications and relevant given BioSkryb's APAC distributor network.
Direct peers
- Mission Bio: Single-cell DNA sequencing and multiomics platform (Tapestri) focused on oncology, MRD, and genomic profiling. Overlaps directly with BioSkryb's ResolveSEQ MRD application and ResolveOME multiomics positioning.
Others
- PacBio: Long-read sequencing platform with single-cell Iso-Seq and HiFi applications. Relevant as a potential complementary downstream for BioSkryb's ResolveSEQ LongRead early-access product.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BioSkryb Genomics social profiles
Digital presenceBioSkryb Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioSkryb Genomics leadership team
Management profileNumber of profiles
Profiles8 records
BioSkryb Genomics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioSkryb Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioSkryb Genomics
What does BioSkryb Genomics do?
BioSkryb Genomics develops and sells single-cell whole genome amplification kits (ResolveDNA, ResolveOME), sequencing services (ResolveSEQ MRD, ScreenHT, LongRead), and the BaseJumper bioinformatics platform, all powered by its patented Primary Template-directed Amplification (PTA) technology. The offering enables researchers to capture >97% of the genome along with full-length transcriptome and surface protein data from the same single cell in a single-day workflow.
Is BioSkryb Genomics a public or private company?
BioSkryb Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioSkryb Genomics founded?
BioSkryb Genomics was founded in 2018. It employs 11 to 50 people.
Where is BioSkryb Genomics based?
BioSkryb Genomics is headquartered in Durham, United States, in the North America region.
How does BioSkryb Genomics make money?
Three revenue lines are on record. Product Sales (Kits and Consumables) is the primary driver. The others are contract Services (ResolveServices) and AI Dataset Partnerships.
Who are BioSkryb Genomics's main competitors?
Broad incumbents on record are Illumina, 10x Genomics, Takara Bio (SMART-seq) and BD (BD Biosciences - Rhapsody). Emerging players are Element Biosciences, Parse Biosciences, Ultima Genomics and Singleron Biotechnologies. Mission Bio is listed as a direct peer. PacBio is listed as an others.
Does BioSkryb Genomics have an API?
No public API is recorded for BioSkryb Genomics.
What industry is BioSkryb Genomics in?
BioSkryb Genomics's product category is Single-Cell Genomics Tools and Reagents. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714 and its SIC code is 8731.